Show simple item record

dc.contributor.authorMantero, Julio C.
dc.date.accessioned2016-02-25T19:20:30Z
dc.date.issued2016
dc.identifier.urihttps://hdl.handle.net/2144/14607
dc.description.abstractInterstitial lung disease is one of the main causes of mortality in Systemic Sclerosis. The course of the disease is clinically variable where patients can suffer from a range of stable disease to rapid progressive clinical deterioration. Therefore, it is important to identify biomarkers that can predict the clinical course of patients in order to provide early treatment. We evaluated 1129 proteins utilizing novel high-throughput SOMAlogic proteomic technology from the serum of 13 LSSc, 13 progressive ILD and 11 stable ILD patients. Calpain-1 was significantly elevated in progressive ILD patients (median 15129 RFU, 11091-24561) compared to LSSc patients (12759, 9904-15498, p=0.0015) and stable ILD patients (11876, 10271-14249, p=0.0005). Coagulation Factor V was significantly lower in the progressive ILD patients (7161 RFU, 2140-8296) compared to LSSc patients (10311 RFU, 6396-12260, p=0.001) and stable ILD patients (9646 RFU, 6510-11941, p=0.0016). The combination of Coagulation Factor V and Calpain-1 produced an area under the curve of 0.97 (95% CI, 0.921-0.99), sensitivity of 99% and specificity of 91% for the identification of progressive ILD. We have identified a combination of proteins that show potential to be prognostic biomarkers for ILD in SSc.en_US
dc.language.isoen_USen_US
dc.subjectMedicineen_US
dc.subjectBiomarkersen_US
dc.subjectILDen_US
dc.subjectSystemic sclerosisen_US
dc.titlePilot study: prognostic biomarkers for interstitial lung disease in systemic sclerosisen_US
dc.typeThesis/Dissertation
dc.date.updated2016-02-17T20:20:15Z
dc.description.embargo2016-12-31T00:00:00Z
etd.degree.nameMaster of Scienceen_US
etd.degree.levelmastersen_US
etd.degree.disciplineClinical Investigationen_US
etd.degree.grantorBoston Universityen_US


This item appears in the following Collection(s)

Show simple item record